FY2028 EPS Estimates for Travere Therapeutics, Inc. (NASDAQ:TVTX) Cut by Analyst

Travere Therapeutics, Inc. (NASDAQ:TVTX) – Stock analysts at HC Wainwright cut their FY2028 earnings per share (EPS) estimates for shares of Travere Therapeutics in a research report issued to clients and investors on Wednesday, April 24th. HC Wainwright analyst E. Arce now forecasts that the company will earn $4.29 per share for the year, down from their previous forecast of $4.66. HC Wainwright has a “Buy” rating and a $19.00 price target on the stock. The consensus estimate for Travere Therapeutics’ current full-year earnings is ($3.10) per share.

Several other brokerages have also recently weighed in on TVTX. Wells Fargo & Company increased their target price on Travere Therapeutics from $8.00 to $9.00 and gave the company an “equal weight” rating in a report on Friday, February 16th. Wedbush reiterated an “outperform” rating and issued a $13.00 price objective on shares of Travere Therapeutics in a report on Wednesday, April 17th. Guggenheim reiterated a “neutral” rating on shares of Travere Therapeutics in a report on Wednesday, March 27th. Finally, Piper Sandler increased their price objective on Travere Therapeutics from $10.00 to $11.00 and gave the stock a “neutral” rating in a report on Thursday, January 18th. Six analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $18.00.

Travere Therapeutics Trading Down 1.1 %

Shares of TVTX stock opened at $5.39 on Thursday. The stock has a market capitalization of $410.23 million, a PE ratio of -3.35 and a beta of 0.58. Travere Therapeutics has a 1-year low of $5.12 and a 1-year high of $22.75. The business has a 50-day moving average of $7.34 and a 200 day moving average of $7.66. The company has a debt-to-equity ratio of 1.88, a current ratio of 3.47 and a quick ratio of 3.41.

Travere Therapeutics (NASDAQ:TVTX) last issued its earnings results on Thursday, February 15th. The company reported ($1.16) earnings per share for the quarter, beating the consensus estimate of ($1.27) by $0.11. The company had revenue of $45.06 million during the quarter, compared to analysts’ expectations of $41.25 million. Travere Therapeutics had a negative return on equity of 177.97% and a negative net margin of 56.02%.

Insider Transactions at Travere Therapeutics

In other news, insider Peter Heerma sold 4,195 shares of the stock in a transaction that occurred on Thursday, February 1st. The stock was sold at an average price of $8.53, for a total value of $35,783.35. Following the completion of the transaction, the insider now owns 99,503 shares of the company’s stock, valued at approximately $848,760.59. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, insider Peter Heerma sold 4,195 shares of the firm’s stock in a transaction that occurred on Thursday, February 1st. The stock was sold at an average price of $8.53, for a total transaction of $35,783.35. Following the completion of the transaction, the insider now owns 99,503 shares of the company’s stock, valued at approximately $848,760.59. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, CFO Christopher R. Cline sold 3,818 shares of the firm’s stock in a transaction that occurred on Thursday, February 1st. The shares were sold at an average price of $8.53, for a total value of $32,567.54. Following the transaction, the chief financial officer now directly owns 70,903 shares of the company’s stock, valued at approximately $604,802.59. The disclosure for this sale can be found here. In the last quarter, insiders sold 34,773 shares of company stock valued at $300,625. Corporate insiders own 3.75% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Armistice Capital LLC increased its position in Travere Therapeutics by 0.7% during the 3rd quarter. Armistice Capital LLC now owns 7,500,000 shares of the company’s stock valued at $67,050,000 after buying an additional 50,000 shares in the last quarter. Vanguard Group Inc. increased its position in Travere Therapeutics by 10.9% during the 3rd quarter. Vanguard Group Inc. now owns 4,667,458 shares of the company’s stock valued at $41,727,000 after buying an additional 460,176 shares in the last quarter. Kynam Capital Management LP increased its holdings in shares of Travere Therapeutics by 105.6% in the 4th quarter. Kynam Capital Management LP now owns 2,000,000 shares of the company’s stock worth $17,980,000 after purchasing an additional 1,027,398 shares in the last quarter. Jacobs Levy Equity Management Inc. increased its holdings in shares of Travere Therapeutics by 9.6% in the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 1,671,770 shares of the company’s stock worth $14,946,000 after purchasing an additional 146,970 shares in the last quarter. Finally, Finepoint Capital LP increased its holdings in shares of Travere Therapeutics by 60.2% in the 4th quarter. Finepoint Capital LP now owns 1,435,321 shares of the company’s stock worth $12,904,000 after purchasing an additional 539,500 shares in the last quarter.

Travere Therapeutics Company Profile

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.